Urogen Pharma Ltd 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Urogen Pharma Ltd 's ROA in the second quarter of 2026?
Urogen Pharma Ltd recorded a cumulative net loss of $-98 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -34.72%.

However, within the Healthcare sector 523 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4059, from total ROA ranking in the first quarter of 2026 at 4827.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	21.02 %	2.45 %	11.33 %	5.22 %	-19.95 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-98	-133	-153	-165	-155
Return On Assets (TTM)	-34.72 %	-49.3 %	-57.12 %	-63.89 %	-60.67 %
URGN's Total Ranking	# 4059	# 4827	# 4217	# 4182	# 4148
Total Assets (TTM) in million	253	254	434	185	209
Seq. Total Assets Change	-0.43 %	-41.49 %	134.3 %	-11.34 %	-15.71 %
Seq. Net Income Change	-	-	-	-	-

URGN's 5 Years Annual ROA >> Back to URGN Management Effectiveness >> Compare URGN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 216
Sector	# 524
Overall	# 3812

Return On Assets Statistics
High	Average	Low
-26.47 %	-67.1 %	-92.33 %
(Dec 31 2017)		(Jun 30 2023)

Financial Statements
Urogen Pharma Ltd 's Assets	$ 253 million	URGN's Balance sheet
Urogen Pharma Ltd 's Income	$ -14 million	Quarterly URGN's Income Statement
URGN's Income by Division		See URGN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	11.33 %	38.83 %	28.2 %	26.66 %	17.57 %
Total Assets in million	434	389	280	219	173
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-153	-127	-102	-110	-111
Annual Return On Assets	-35.4 %	-32.58 %	-36.45 %	-50.18 %	-64.15 %

URGN's 5 Years Annual ROA >> Back to URGN Management Effectiveness >> Compare URGN ROA to its Competitors

More Return On Assets Ratios
URGN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
URGN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for URGN's Competitors
Subscribers only: Roa for Urogen Pharma Ltd 's Suppliers
Subscribers only: Return On Assets for URGN's Customers

You may also want to know
URGN's Roi	URGN's Inventory Turnover Ratio	URGN's Growth Rates	URGN's Dividend Comparisons
	URGN's Profitability Ratios	URGN's Asset Turnover Ratio	URGN's Dividend Growth
URGN's Roe	URGN's Valuation Ratios	URGN's Financial Strength Ratios	URGN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-09T22:40:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.